Surgery – Blood drawn and replaced or treated and returned to body – Constituent removed from blood and remainder returned to body
Reexamination Certificate
2007-04-10
2007-04-10
Blanco, Patricia (Department: 3772)
Surgery
Blood drawn and replaced or treated and returned to body
Constituent removed from blood and remainder returned to body
C604S005010, C422S044000, C424S140100, C210S646000, C210S651000
Reexamination Certificate
active
10391443
ABSTRACT:
A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50–75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator fromStaphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.
REFERENCES:
patent: 3797485 (1974-03-01), Uruhart
patent: 4464166 (1984-08-01), Edelson
patent: 4559034 (1985-12-01), Kirita et al.
patent: 4683889 (1987-08-01), Edelson
patent: 4708715 (1987-11-01), Troutner et al.
patent: 4737140 (1988-04-01), Lee et al.
patent: 4950225 (1990-08-01), Davidner et al.
patent: 5104373 (1992-04-01), Davidner et al.
patent: 5288605 (1994-02-01), Lin et al.
patent: 5433738 (1995-07-01), Stinson
patent: 5459030 (1995-10-01), Lin et al.
patent: 5496637 (1996-03-01), Parham et al.
patent: 5730713 (1998-03-01), Okarma et al.
patent: 5910252 (1999-06-01), Truitt et al.
patent: 5910307 (1999-06-01), Kwak et al.
patent: 5951509 (1999-09-01), Morris
patent: 6039946 (2000-03-01), Strahilevitz
patent: 6042783 (2000-03-01), Nagamatsu et al.
patent: 6193681 (2001-02-01), Davidner et al.
patent: 2004/0182783 (2004-09-01), Walker et al.
patent: 406285159 (1994-10-01), None
DiGiovine, Burno et al. “The Attributable Mortality and Costs of primary Nosocomial Bloodstream Infections in the Intensive Care Unit” American Journal of Respiratory and Critical Care Medicine, vol. 160, 1999: pp. 976-981.
Bellomo, Rinaldo et al. “The Effect of Intensive Plasma Water Exchange by Hemofiltration on Hemodynamics and Soluble Mediators in Canine Endotoxemia” American Journal of Respiratory and Critical Care Medicine, vol. 161, 2000: pp. 1429-1436.
Talmor, Mia, M.D. et al. “Relationship of Systemic Inflammatory Response Syndrome to Organ Dysfunction, Length of Stay, and Mortality in Critical Surgical Illness” Arch Surg. vol. 134, 1999: pp. 81-87.
Amura, Claudia R., et al. “Mechanisms Involved in the Pathogenesis of Sepsis Are Not Necessarily Reflected by In Vitro Cell Activation Studies” Infection and Immunity, vol. 66, No. 11, Nov. 1998: pp. 5372-5378.
Wenzel, Richard P, M.D. “Treating Sepsis” New England Journal of Medicine, vol. 347, No. 13, Sep. 26, 2002: pp. 966-967.
Cole, Louise, MBBS, Fficanzca et al. “A Phase II Randomized, Controlled Trial of Continuous Hemofiltration in Sepsis” Critical Care Medicine, vol. 30, No. 1, 2002: pp. 100-106.
Ronco, Claudio, M.D. et al. “A Pilot Study of Coupled Plasma Filtration with Adsorption in Septic Shock” Crit Care Med, vol. 30, No. 6, 2002: pp. 1250-1255.
Bernard, Gordon R., M.D. et al. “Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis” The New England Journal of Medicine, vol. 344, No. 10, Mar. 8, 2001: pp. 699-709.
Murray, Patrick et al. “Renal Replacement Therapy for Acute Renal Failure” American Journal of Respiratory and Critical Care Medicine, vol. 162, 2000: pp. 777-781.
Osarogiagbon, U. Raymond et al. “Reperfusion Injury Pathophysiology in Sickle Transgenic Mice” Blood, vol. 96, No. 1, Jul. 1, 2000: pp. 314-320.
Warren, H. Shaw, M.D. et al. “Risks and Benefits of Activated Protein C Treatment for Severe Sepsis” The New England Journal of Medicine, vol. 347, No. 13, Sep. 26, 2002: pp. 1027-1030.
Stegmayr, Bernd G. “Is There a Future for Adsorption Techniques in Sepsis” Blood Purification, vol. 18, 2000: pp. 149-155.
Asmis, Reto et al. “Vitamin E. Supplementation of Human Macrophages Prevents Neither Foam Cell Formation Nor Increased Susceptibility of Foam Cells to Lysis by Oxidized LDL” Arteriorscler Thromb Vascular Biology, Sep. 2000, pp. 2078-2086.
Carr, Antra C. et al. “Potential Antiatherogenic Mechanisms of Ascorbate (Vitamin C) and α—Tocopherol (Vitamin E)” Circulation Research, Sep. 1, 2000, pp. 349-354.
Segerer, Stephan et al. “Chemokines, Chemokin Receptors, and Renal Disease: From Basic Science To Pathophysiologic and Therapeutic Studies” Journal of American Soceity of Nephrology, vol. 11, 2000: pp. 152-176.
Forni, L.G., M.B., Ph.D. and Hilton, P.J., M.D. “Continuous Hemofiltration in the Treatment of Acute Real Failure” The New England Journal of Medicine, vol. 336, No. 18, May 1, 1997: pp. 1303-1309.
Schindler, Ralf et al. “Influencing the Inflammatory Response of Haemodialysis Patients by Cytokiine Elimination Using Large-Pore Membranes” Nephrol Dial Transplant (2002), Editorial Comments. Pp 17-19.
De Vriese, An. S. et al. “Cytokine Removal During Continuous Hemofiltration in Septic Patients” Journal of American Society of Nephrol, vol. 10, 1999: pp. 846-853.
Matic, Goran et al. “Extracorporeal Removal of Circulating Immune Complexes: From Non-Selective to Patient-Specific” Blood Purification, vol. 18, 2000: pp. 156-160.
Roshchupkin, D.K. and Murina, M.A. “Free-Radical and Cyclooxygenase-Catalyzed Lipid Peroxidation in Membranes of Blood Cells Under UV Irradiation” Membrane Cell Biology, vol. 12, No. 1998: pp. 279-286.
Ward, Richard A. et al. “ A Comparison of On-Line Hemodiafiltration and High-Flux hemodialysis: A Prospective Clinical Study” Journal of American Society of Nephrol, vol. 11, 2000: pp. 2344-2350.
Depner, Thomas, M.D. et al. “Lessons from the Hemodialysis (HEMO) Study: An Improved Measure of the Actual Hemodialysis Dose” American Journal of Kidney Diseases, vol. 33, No. 1, Jan. 1999: pp. 142-149.
Davidner Alan A.
Mallett Scott R.
Walker Kimberly A.
Blanco Patricia
Hemavation, LLC
Knobbe Martens Olson & Bear LLP
LandOfFree
Device and method for reducing inflammatory mediators in blood does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Device and method for reducing inflammatory mediators in blood, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Device and method for reducing inflammatory mediators in blood will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3747553